Giulio Ricotta

ORCID: 0000-0001-5897-5650 · 5 papers in corpus
2026
Adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies is associated with improved survival in patients with pelvic lymph node metastasis: a sub-analysis from the COREPEX study
·doi:10.1016/j.ijgc.2025.103065
review 2025
Endometrial Stromal Sarcoma: An Update
Cancers ·doi:10.3390/cancers17111893

Endometrial stromal sarcoma (ESS) is a rare malignant tumor of uterine mesenchyme, accounting for 15-20% of uterine sarcomas. It is classified into low-grade (LG-ESS) and high-grade (HG-ESS) subtypes, each defined by distinct histopathologi…

2022
2022-RA-173-ESGO Endometrioid borderline ovarian tumor: clinical characteristics, prognosis and management
·doi:10.1136/ijgc-2022-esgo.480
other 2022
Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements
Annals of surgical oncology ·doi:10.1245/s10434-022-11893-7

BACKGROUND: Endometrioid borderline ovarian tumor (EBOT) is a rare subtype of borderline ovarian malignancies. This study was designed to determine the prognosis of a series of EBOT. METHODS: This is a retrospective review of patients with…

other 2021
Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management
Annals of surgical oncology ·doi:10.1245/s10434-021-10776-7

BACKGROUND: Clear cell borderline ovarian tumor (CCBOT) is one of the rarest subtypes of borderline ovarian malignancies. The aim of this study was to determine the prognosis of a series of CCBOT. PATIENTS AND METHODS: A retrospective revi…